Christopher McGuigan
Plus aucun poste en cours
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
John Brancaccio | M | 76 |
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | 19 ans |
Mark Erlander | M | 64 | 11 ans | |
Rodney Markin | M | 67 | 10 ans | |
Willy Simon | M | 72 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 9 ans |
John Cavan | M | 65 | 8 ans | |
Timothy Block | M | 69 | 11 ans | |
Erik de Clercq | M | - |
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | 19 ans |
Richard Whitley | M | 78 |
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | 19 ans |
Neil Warren | M | - |
University of Cardiff
| 30 ans |
David Simpson | M | 67 |
University of Cardiff
| 11 ans |
Donald Munoz | M | 56 | 9 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Gary Jacob | M | 77 | 11 ans | |
Russell H. Plumb | M | 65 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 12 ans |
Gabriele Cerrone | M | 52 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA.
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | 8 ans |
Phillip James Boyd | M | 61 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 1 ans |
Joseph Patti | M | 60 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 18 ans |
Demetrios Kydonieus | M | 54 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | - |
Theresa Matkovits | M | 56 | 3 ans | |
Bernard Denoyer | M | 77 | 1 ans | |
Michael Barrett | M | 81 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 10 ans |
Geoffrey W. Henson | M | 76 |
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | 2 ans |
Anna Novotney-Barry | F | - |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 2 ans |
Paul Billings | M | 71 | - | |
Luis Pinheiro de Matos | M | - |
University of Cardiff
| 6 ans |
David T. Bonk | M | - |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | - |
Andrew Jolly | M | 53 |
University of Cardiff
| 4 ans |
Marc L. Preminger | M | 74 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 9 ans |
P. Campisi | M | 63 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | - |
Arnold Lippa | M | 77 | 8 ans | |
Mike A. Henos | M | 75 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 15 ans |
Russell Medford | M | 69 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 15 ans |
Katherine Reynolds Kelly | F | 48 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | - |
A. Keith Willard | M | 83 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 7 ans |
James Sapirstein | M | 63 | 4 ans | |
Yu Lei Shi | M | - |
University of Cardiff
| 1 ans |
Tariq Abaulaziz Al-Hamad | M | - |
University of Cardiff
| 3 ans |
Michael J. Terry | M | 69 | 2 ans | |
Sing Chia Tan | F | 35 |
University of Cardiff
| 4 ans |
David Woolliscroft | M | 65 |
University of Cardiff
| 3 ans |
Matthew Owen Gingell | M | 45 |
University of Cardiff
| 3 ans |
Morgan Johnson | F | - |
University of Cardiff
| 3 ans |
Darshan Chandaria | M | - |
University of Cardiff
| 3 ans |
Ivan Lim | M | - |
University of Cardiff
| 2 ans |
Katie Priddis | F | - |
University of Cardiff
| 3 ans |
Rong Li Yuan | M | 52 |
University of Cardiff
| 3 ans |
Richard O’Brien | M | 48 |
University of Cardiff
| 4 ans |
Gareth Davies | M | - |
University of Cardiff
| 3 ans |
David Richardson | M | - |
University of Cardiff
| 3 ans |
Kabir Kumar Nath | M | 59 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | - |
Will Martin | M | - |
University of Cardiff
| 3 ans |
Steve Chaves | M | - |
University of Cardiff
| 4 ans |
Li Ning Li | F | 48 |
University of Cardiff
| 1 ans |
George Salmon | M | - |
University of Cardiff
| 3 ans |
Joe Winstanley | M | - |
University of Cardiff
| 4 ans |
Raju Hussain | M | - |
University of Cardiff
| 10 ans |
John Stevens | M | - |
University of Cardiff
| 4 ans |
Christian Jones | M | - |
University of Cardiff
| 3 ans |
Matt Jackson | M | - |
University of Cardiff
| 3 ans |
Guto Davies | M | - |
University of Cardiff
| 2 ans |
Saqib Anjum | M | - |
University of Cardiff
| 2 ans |
Tim Bary | M | - |
University of Cardiff
| 3 ans |
Harry Bartlett | M | - |
University of Cardiff
| 4 ans |
Isabelle Richards | F | - |
University of Cardiff
| 4 ans |
Na Qiong Tong | M | 44 |
University of Cardiff
| 2 ans |
Azmi Bin Hassan | M | 57 |
University of Cardiff
| 3 ans |
Wai Cheong Law | M | 38 |
University of Cardiff
| 3 ans |
Richard Patrick Avery-Wright | M | 56 |
University of Cardiff
| 3 ans |
Adam Herron | M | 50 |
University of Cardiff
| 4 ans |
Louis Sullivan | M | 90 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | - |
David Moskowitz | M | - | - | |
Carl E. Brooks | M | - |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | - |
Robert A. Hamm | M | 72 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 4 ans |
Frederick Larcombe | M | 67 |
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | 2 ans |
Simon Wilsher | M | - |
University of Cardiff
| 4 ans |
John Z. Sullivan-Bólyai | M | 76 | 2 ans | |
Oanh Dang | M | - | 1 ans | |
John H. Vernachio | M | - |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 14 ans |
Amir Aviv | M | 52 |
University of Cardiff
| 4 ans |
Chris Chiverton | M | - |
University of Cardiff
| 4 ans |
David Jeans | M | 74 |
University of Cardiff
| 5 ans |
Uday Patel | M | - |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 2 ans |
Jeffrey Galik | M | - |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | - |
Gang Wei | M | 49 |
University of Cardiff
| 3 ans |
Mandhir Singh | M | 57 |
University of Cardiff
| 1 ans |
Anish Bansal | M | 39 |
University of Cardiff
| 4 ans |
Philip Shucksmith | M | - |
University of Cardiff
| 4 ans |
Majdi Omer Ahmed Barjous | M | 65 |
University of Cardiff
| 3 ans |
Tiziano Lazzaretti | M | 65 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | - |
Saeed Mubarak Al-Muharrami | M | - |
University of Cardiff
| 3 ans |
Jim Tripp | M | 54 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | - |
Ahmad bin Abd Malek | M | 49 |
University of Cardiff
| 4 ans |
Ryan Weir | M | - |
University of Cardiff
| 4 ans |
Vlada Melnikova | M | - | 2 ans | |
Mohamed Al-Mamari | M | - |
University of Cardiff
| 1 ans |
Andrew Mark Gutmann | M | 54 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | - |
Victoria Coupe | F | - |
University of Cardiff
| 2 ans |
Bijal N. Patel | F | - |
University of Cardiff
| 3 ans |
Ahmed bin Saleh Al-Dehailan | M | - |
University of Cardiff
| 3 ans |
Emma Burns | F | - |
University of Cardiff
| 4 ans |
Declan McEvilly | M | - |
University of Cardiff
| 3 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Royaume-Uni | 55 | 55,00% |
Etats-Unis | 40 | 40,00% |
Bermudes | 5 | 5,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Christopher McGuigan
- Réseau Personnel